Shopping Cart
- Remove All
- Your shopping cart is currently empty
Inetetamab is a humanized monoclonal antibody targeting HER2 receptor domain IV, exhibiting antitumor activity through inducing pyroptosis in lung adenocarcinoma. It is used in studies of HER2-positive metastatic breast cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $289 | In Stock | |
5 mg | $753 | In Stock | |
10 mg | $1,230 | In Stock | |
25 mg | $1,830 | In Stock | |
50 mg | $2,480 | In Stock |
Description | Inetetamab is a humanized monoclonal antibody targeting HER2 receptor domain IV, exhibiting antitumor activity through inducing pyroptosis in lung adenocarcinoma. It is used in studies of HER2-positive metastatic breast cancer. |
In vitro | Inetetamab is a novel anti-HER2 monoclonal antibody. In combination with cisplatin, inetetamab increases ROS levels by inhibiting HER2/AKT/Nrf2 signaling, thereby triggering NLRP3/caspase-1/GSDMB mediated pyroptosis. Synergistically enhance the anti-tumor efficacy of LUAD cells. [1] |
In vivo | Inetetamab (20 mg/kg intraperitoneally injected) showed antitumor effects in JIMT-1 xenograft mouse models. Inetetamab (20 mg/kg intraperitoneally injected) in combination with Pyrotinib or Cyclophosphamide demonstrated significant antitumor effects in JIMT-1 and NCI-N87 xenograft mouse models. [2] |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.